All In Biotech

Drug Trial Radar · NCT00151762

Long-Term Study of Safety and Efficacy of WelChol® as an Additional Therapy in Patients With Type 2 Diabetes

A Multi-Center, 52-Week, Open-Label Extension Study (From Studies WEL-301, WEL-302, and WEL-303) to Evaluate the Long-Term Safety and Tolerability of WelChol® in Type 2 Diabetic Patients

Last checked: Nov 19, 2026Latest source record: Jan 9, 2008 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

780

Actual

Start

Dec 2004

Primary completion

Jul 2007

Study completion Jul 2007

Sponsor

Lead sponsor
Daiichi SankyoDaiichi Sankyo (DSNKY)
Sponsor type
Industry
First posted
Sep 9, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This extension study is designed to evaluate the long-term safety and tolerability of colesevelam hydrochloride (WelChol®) in patients with type 2 diabetes.

Conditions

  • Type 2 Diabetes

Interventions

  • Colesevelam hydrochlorideDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate safety and tolerability of colesevelam hydrochloride as add-on therapy

Locations

64 sites in 3 countries. Site status is shown where the registry gives one.

  • Site not named

    Birmingham, Alabama

  • Site not named

    Tuscumbia, Alabama

  • Site not named

    Jonesboro, Arkansas

  • Site not named

    Little Rock, Arkansas

  • Site not named

    Searcy, Arkansas

  • Site not named

    Carmichael, California

  • Site not named

    Concord, California

  • Site not named

    Irvine, California

  • Site not named

    La Jolla, California

  • Site not named

    Los Angeles, California

  • Site not named

    Los Gatos, California

  • Site not named

    San Diego, California

  • Site not named

    Spring Valley, California

  • Site not named

    West Hills, California

  • Site not named

    Washington D.C., District of Columbia

  • Site not named

    Cocoa Beach, Florida

  • Site not named

    Coral Gables, Florida

  • Site not named

    Largo, Florida

  • Site not named

    Miami, Florida

  • Site not named

    New Port Richey, Florida

  • Site not named

    Pembroke Pines, Florida

  • Site not named

    West Palm Beach, Florida

  • Site not named

    Atlanta, Georgia

  • Site not named

    Chicago, Illinois

  • Site not named

    Evansville, Indiana

  • Site not named

    Indianapolis, Indiana

  • Site not named

    Lexington, Kentucky

  • Site not named

    Louisville, Kentucky

  • Site not named

    New Orleans, Louisiana

  • Site not named

    Boston, Massachusetts

  • Site not named

    Detroit, Michigan

  • Site not named

    Troy, Michigan

  • Site not named

    Edina, Minnesota

  • Site not named

    Kansas City, Missouri

  • Site not named

    St Louis, Missouri

  • Site not named

    Bozeman, Montana

  • Site not named

    Butte, Montana

  • Site not named

    Las Vegas, Nevada

  • Site not named

    Rochester, New York

  • Site not named

    Charlotte, North Carolina

Showing 40 of 64 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.